Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18641686 | 1.00 | TSHR (0.54) | TSHRLMNAALDH1A1PAOXEPHX2 | |
| SCHEMBL23132220 | 1.00 | TSHR (0.54) | TSHRLMNAALDH1A1PAOXEPHX2 | |
| SCHEMBL20283628 | 0.92 | TSHR (0.64) | TSHRLMNAALDH1A1PAOXEPHX2 | |
| SCHEMBL8214934 | 0.92 | TSHR (0.64) | TSHRLMNAALDH1A1PAOXEPHX2 | |
| SCHEMBL2586098 | 0.92 | TSHR (0.64) | TSHRLMNAALDH1A1PAOXEPHX2 | |
| SCHEMBL16730520 | 0.92 | TSHR (0.64) | TSHRLMNAALDH1A1PAOXEPHX2 | |
| SCHEMBL18970748 | 0.90 | TP53 (0.45) | TSHRLMNAALDH1A1EPHX2HSD17B10 | |
| Hydrochloric Acid SCHEMBL2579652 | 0.90 | TSHR (0.61) | TSHRLMNAALDH1A1PAOXEPHX2 | |
| Hydrochloric Acid SCHEMBL2583424 | 0.90 | TSHR (0.61) | TSHRLMNAALDH1A1PAOXEPHX2 | |
| SCHEMBL13903715 | 0.84 | CA12 (0.59) | TSHRLMNAALDH1A1EPHX2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133946-A1 | CATIONIC LIPID COMPOUND, COMPOSITION CONTAINING SAME AND USE THEREOF | 杭州天龙药业有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023098842-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 OMICRON STRAIN | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023056911-A1 | MULTIVALENT NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 BETA AND DELTA STRAINS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-04-13 | — | — | WO | disclosed |
| US-11472766-B2 | Lipid nanoparticle composition | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2022-10-18 | — | — | US | disclosed |
| US-20220153686-A1 | LIPID NANOPARTICLE COMPOSITION | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-9791450-B2 | Fluorescent compounds | BIOTIUM, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9791450-B2 | Fluorescent compounds | BIOTIUM, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2223086-B2 | FLUORESCENT COMPOUNDS - LABELING DYES | BIOTIUM INC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20160033520-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160033520-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9097667-B2 | Fluorescent compounds | BIOTIUM, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20090305410-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153686-A1 | LIPID NANOPARTICLE COMPOSITION | CETP, NPC1, LCAT | TSHR 4385/4885LMNA 218/4885ALDH1A1 4587/4885 |
| US-20090305410-A1 | FLUORESCENT COMPOUNDS | MKI67, CD68, CA5B | TSHR 4234/4885LMNA 539/4885ALDH1A1 62/4885 |
| US-11472766-B2 | Lipid nanoparticle composition | CETP, NPC1, LCAT | TSHR 4385/4885LMNA 218/4885ALDH1A1 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.